CHI 2012

Chi Election 2012 PNG Gradient

Online Registration Ends Friday, Nov. 2

CHI’s Annual Meeting is focused on the relationship between biomedical innovation and public policy. This event brings together delegates from more than 200 of CHI’s member organizations with policymakers to discuss critical issues and opportunities facing the biomedical community. The goal of the forum is to produce a clearer understanding of the biomedical community’s work and needs, and how the industry can sustain California’s leadership in medical innovation. Below, please find the agenda at a glance with confirmed speakers to date.

Agenda At A Glance  

8:00 to 9:00 a.m. Networking breakfast and registration 
9:00 to 9:10 a.m. Opening remarks and Introduction

  • John Martin, Ph.D., Chairman of the Board & CEO, Gilead Sciences
  • David Gollaher, Ph.D., President & CEO, California Healthcare Institute
9:10 to 9:30 a.m. Salon Interactive

  • Assemblywoman Fiona Ma, CPA, Speaker Pro Tempore (12th District)
9:30 to 10 a.m. Decision 2012: Understanding the Outcome of the Election

  • David Beier, Senior Vice President, Amgen
  • David Gollaher, President & CEO, California Healthcare Institute
10 to 10:30 a.m. Keynote

  • Dr. Mark Smith, President & CEO, California HealthCare Foundation
10:30 to 11:30 a.m. Regulatory Approaches to Benefit and Risk: A Global Perspective

  • Moderator: Coleen Klasmeier, Head, FDA Regulatory Practice, Sidley Austin
  • Michael Narachi, President & CEO, Orexigen
  • Vincenzo Salvatore, Senior Counsel, Sidley Austin LLP
  • Hank Greely, Professor of Law and Director, Center for Law and the Biosciences, Stanford University
  • Clay Alspach, Counsel, House Energy & Commerce Committee, U.S. House of Representatives
11:30 a.m. to 1 p.m. Luncheon Keynote

  • Tom Campbell, Dean of the School of Law, Chapman University
1 to 1:30 p.m. The New Healthcare Marketplace

  • Daniel Mendelson, CEO and Founder, Avalere
1:30 p.m. to 2:00 p.m. FDA Scorecard

  • Dirk Calcoen, Partner & Managing Director, The Boston Consulting Group
  • Mark Lubkeman, Senior Partner & Managing Director, The Boston Consulting Group
2 to 2:30 p.m. Salon Interactive

  • Director Kish Rajan, Governor’s Office of Business and Economic Development – GO-Biz
2:30 to 3 p.m. NETWORKING BREAK
3 to 4 p.m. Economic and Public Health Impact of Federal Funding of Basic Research

  • Margaret Anderson, Executive Director, Faster Cures
  • Dr. Michael Friedman, CEO, Director, Comprehensive Cancer Center, City of Hope
  • Alan Malus, Executive Vice President & President of the Analytical Technologies Group, Thermo Fisher
4 to 5 p.m. The Innovation Continuum: Balancing Stakeholder Demands

  • Bryan Giraudo, Managing Partner, Leerink Swann
  • Kevin Gorman, Ph.D., CEO, Neurocrine Biosciences,
  • Paul Hastings, President & CEO, OncoMed Pharmaceuticals